http://novacyt.com/wp-content/uploads/2019/06/Novacyt-Note-Conversion-7_FRENCH_14.06.19-FINAL.pdf
Visit PageNews and Events
Conversion of Loan Notes
http://novacyt.com/wp-content/uploads/2019/06/Novacyt-Note-Conversion-7_ENGLISH_14.06.19-FINAL.pdf
Visit PagePublication du rapport annuel et de l’avis de convocation à l’Assemblée générale des actionnaires
http://novacyt.com/wp-content/uploads/2019/05/Novacyt-Publication-of-Annual-Report-and-Notice-of-AGM_FRENCH-24-05-19-002.pdf Paris, France et Camberley, Royaume-Uni – 24 mai 2019 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste international du diagnostic clinique, annonce aujourd’hui la publication du rapport annuel du Groupe pour l’exercice clos le 31 décembre 2018, disponible sur le site Internet du Groupe. La version imprimée du rapport annuel sera
Visit PagePublication of Annual Report and Notice of AGM
Paris, France and Camberley, UK – 24 May 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces that the Company’s Annual Report and Accounts (“Annual Report”) for the year ended 31 December 2018 has been published and uploaded to the Company’s website. The Annual Report will also be
Visit PageConversion of Loan Notes
Paris, France and Camberley, UK – 17 May 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) an international specialist in clinical diagnostics, announces that, pursuant to the Convertible Bonds with Warrants Funding Programme announced on 23 April 2019, it has issued a tranche of new ordinary shares of €1/15 each (“Ordinary Shares”) to Negma Group
Visit PageConversion d’OCABSA
Paris, France et Camberley, UK – 17 mai 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), spécialiste international du diagnostic Clinique, annonce qu’en vertu du Programme de Financement par Obligations Convertibles assorties de Warrants annoncé le 23 avril 2019, elle a émis une tranche d’actions ordinaires nouvelles de 1/15 € chacune (« Actions Ordinaires ») à Negma Group
Visit PageConversion d’OCABSA
Paris, France et Camberley, UK – 15 mai 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), spécialiste international du diagnostic Clinique, annonce qu’en vertu du Programme de Financement par Obligations Convertibles assorties de Warrants (“l’Accord”) annoncé le 23 avril 2019, elle a émis une tranche d’actions ordinaires nouvelles de 1/15 € chacune (“Actions Ordinaires”) à Negma
Visit PageConversion of Loan Notes
Paris, France and Camberley, UK – 15 May 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) an international specialist in clinical diagnostics, announces that, pursuant to the Convertible Bonds with Warrants Funding Programme (“Agreement”) announced on 23 April 2019, it has issued one tranche of new ordinary shares of €1/15 each (“Ordinary Shares”) to Negma
Visit PageLancement d’une nouvelle génération d’instrument qPCR
Paris, France et Camberley, UK – 13 mai 2019 – Novacyt (EURONEXT GROWTH : ALNOV; AIM: NCYT), spécialiste international du diagnostic clinique se félicite d’annoncer aujourd’hui que sa division moléculaire, Primerdesign, lance sa nouvelle génération d’instrument de test moléculaire genesig® q32 qPCR (“q32”), pour compléter l’instrument genesig® q16 (“q16”) déjà générateur de revenus. Compatible avec le
Visit PageLAUNCH OF NEXT-GENERATION qPCR INSTRUMENT
Paris, France and Camberley, UK – 13 May 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular business, Primerdesign, has launched its next-generation genesig® q32 qPCR molecular testing instrument (“q32”), to complement the already revenue generating genesig® q16 instrument (“q16”). Compatible with Novacyt’s catalogue of over
Visit Page